RT-PCR and sequencing of the BCR-ABL1 fusion transcript for qualitative detection of mutations associated with resistance to Gleevec (imatinib) and other tyrosine kinase inhibitors. Analysis includes detection of all mutations recommended by guidelines, including the common T315I, Y253H, E255K/V, F359V/C/I, F317L/V/I/C, T315A, and V299L.
Testing is recommended in CML with poor initial response to Gleevec (imatinib), relapse, or progression to accelerated/blast phase. Presence and identity of mutation may direct management to alternative drugs or stem cell transplant.
- Peripheral blood: 5 mL in EDTA tube.
- Bone marrow: 2 mL in EDTA tube.
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible; specimens <72 hours old preferred.